<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7356583\results\search\disease\results.xml">
  <result pre="MedjcmJournal of Clinical Medicine2077-0383MDPI pmcid: 7356583 doi: 10.3390/jcm9061909jcm-09-01909 : Editorial" exact="Cholesterol" post="in Relation to COVID-19: Should We Care about It?"/>
  <result pre="Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Current data suggest that" exact="infection" post="with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing"/>
  <result pre="license (http://creativecommons.org/licenses/by/4.0/). Abstract Current data suggest that infection with severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) causing corona virus disease-19"/>
  <result pre="(http://creativecommons.org/licenses/by/4.0/). Abstract Current data suggest that infection with severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) causing corona virus disease-19 (COVID-19)"/>
  <result pre="Abstract Current data suggest that infection with severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) causing corona virus disease-19 (COVID-19) seems"/>
  <result pre="to follow a more severe clinical course in patients with" exact="cardiovascular disease" post="(CVD), hypertension, and overweight/obesity. It appears that lipid-lowering pharmacological"/>
  <result pre="follow a more severe clinical course in patients with cardiovascular" exact="disease" post="(CVD), hypertension, and overweight/obesity. It appears that lipid-lowering pharmacological"/>
  <result pre="pharmacological interventions, in particular statins, might reduce the risk of" exact="cardiovascular" post="complications caused by COVID-19 and might potentially have an"/>
  <result pre="S-protein of SARS-CoV-2. Evidence of the importance of cholesterol for" exact="viral" post="entry into host cells could suggest a role for"/>
  <result pre="cells could suggest a role for cholesterol-lowering therapies in reducing" exact="viral" post="infectivity. In addition to their lipid-lowering and plaque-stabilisation effects,"/>
  <result pre="in influenza infection, and statin therapy was shown to increase" exact="viral" post="clearance from the blood during chronic hepatitis C infection."/>
  <result pre="was shown to increase viral clearance from the blood during" exact="chronic hepatitis C" post="infection. Statins may also serve as potential SARS-CoV-2 main"/>
  <result pre="shown to increase viral clearance from the blood during chronic" exact="hepatitis C" post="infection. Statins may also serve as potential SARS-CoV-2 main"/>
  <result pre="SARS-CoV-2 main protease inhibitors, thereby contributing to the control of" exact="viral infection." post="In this review, we elaborate on the role of"/>
  <result pre="role of cholesterol level in the process of the coronavirus" exact="infection" post="and provide a critical appraisal on the potential of"/>
  <result pre="statins in reducing the severity, duration, and complications of COVID-19." exact="atherosclerosis" post="cholesterol coronavirus COVID-19 lipid-lowering therapy SARS-CoV-2 statins 1. Introduction"/>
  <result pre="atherosclerosis cholesterol coronavirus COVID-19 lipid-lowering therapy SARS-CoV-2 statins 1. Introduction" exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the"/>
  <result pre="cholesterol coronavirus COVID-19 lipid-lowering therapy SARS-CoV-2 statins 1. Introduction Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the current"/>
  <result pre="coronavirus COVID-19 lipid-lowering therapy SARS-CoV-2 statins 1. Introduction Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), responsible for the current pandemic"/>
  <result pre="COVID-19 lipid-lowering therapy SARS-CoV-2 statins 1. Introduction Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), responsible for the current pandemic of"/>
  <result pre="the virus [2]. Observational studies of COVID-19 individuals with underlying" exact="cardiovascular disease" post="(CVD) showed that they were at increased risk of"/>
  <result pre="virus [2]. Observational studies of COVID-19 individuals with underlying cardiovascular" exact="disease" post="(CVD) showed that they were at increased risk of"/>
  <result pre="they were at increased risk of severe manifestations of the" exact="disease" post="and mortality [3]. Wang et al. found that SARS-CoV-2"/>
  <result pre="were older and more likely to having underlying comorbidities, including" exact="hypertension" post="(58.3% vs. 21.6%), diabetes (22.2% vs. 5.9%), CVD (25%"/>
  <result pre="likely to having underlying comorbidities, including hypertension (58.3% vs. 21.6%)," exact="diabetes" post="(22.2% vs. 5.9%), CVD (25% vs. 10.8%), and cerebrovascular"/>
  <result pre="21.6%), diabetes (22.2% vs. 5.9%), CVD (25% vs. 10.8%), and" exact="cerebrovascular disease" post="(16.7% vs. 1%) compared to those who did not"/>
  <result pre="diabetes (22.2% vs. 5.9%), CVD (25% vs. 10.8%), and cerebrovascular" exact="disease" post="(16.7% vs. 1%) compared to those who did not"/>
  <result pre="not need ICU treatment [4]. Furthermore, the Chinese Centre for" exact="Disease" post="Control and Prevention published a case series of COVID-19,"/>
  <result pre="was 10.5% (in comparison to 7.3% for diabetes, 6.3% for" exact="chronic" post="respiratory disease, 6.0% for hypertension, and 5.6% for cancer)"/>
  <result pre="10.5% (in comparison to 7.3% for diabetes, 6.3% for chronic" exact="respiratory" post="disease, 6.0% for hypertension, and 5.6% for cancer) [5]."/>
  <result pre="SARS-Cov-2 infection) were more likely to develop COVID-19 complications, including" exact="acute" post="respiratory distress syndrome (ARDS) (57.7% vs. 11.9%), malignant arrhythmias"/>
  <result pre="infection) were more likely to develop COVID-19 complications, including acute" exact="respiratory" post="distress syndrome (ARDS) (57.7% vs. 11.9%), malignant arrhythmias (17.3%"/>
  <result pre="more likely to develop COVID-19 complications, including acute respiratory distress" exact="syndrome" post="(ARDS) (57.7% vs. 11.9%), malignant arrhythmias (17.3% vs. 1.5%),"/>
  <result pre="complications, including acute respiratory distress syndrome (ARDS) (57.7% vs. 11.9%)," exact="malignant" post="arrhythmias (17.3% vs. 1.5%), acute coagulopathy (65.8% vs. 20.0%),"/>
  <result pre="syndrome (ARDS) (57.7% vs. 11.9%), malignant arrhythmias (17.3% vs. 1.5%)," exact="acute" post="coagulopathy (65.8% vs. 20.0%), and acute kidney injury (36.8%"/>
  <result pre="(ARDS) (57.7% vs. 11.9%), malignant arrhythmias (17.3% vs. 1.5%), acute" exact="coagulopathy" post="(65.8% vs. 20.0%), and acute kidney injury (36.8% vs."/>
  <result pre="arrhythmias (17.3% vs. 1.5%), acute coagulopathy (65.8% vs. 20.0%), and" exact="acute" post="kidney injury (36.8% vs. 4.7%), as compared with those"/>
  <result pre="(17.3% vs. 1.5%), acute coagulopathy (65.8% vs. 20.0%), and acute" exact="kidney injury" post="(36.8% vs. 4.7%), as compared with those with normal"/>
  <result pre="especially useful, as they not only reduce the risk of" exact="cardiovascular" post="complications, but may have independent antiviral, anti-inflammatory, and antithrombotic"/>
  <result pre="of cholesterol and cholesterol-lowering therapy. 2. Lipid Rafts, Cholesterol, and" exact="Viral" post="Entry In order to further characterise the underlying mechanisms"/>
  <result pre="which have been shown to play an important role in" exact="viral" post="entry into host cells [12,13]. The abundant presence of"/>
  <result pre="rafts is thought to play an essential role in promoting" exact="viral" post="infectivity [12,13]. Lipid rafts are important for the interaction"/>
  <result pre="ACE2 receptor as well as for facilitating the process of" exact="viral" post="endocytosis [14]. However, the localisation of ACE2 on lipid"/>
  <result pre="may be as important as cholesterol in the process of" exact="viral" post="entry [11] (Figure 1A). The role of cholesterol in"/>
  <result pre="viral entry [11] (Figure 1A). The role of cholesterol in" exact="viral" post="entry has been studied for several coronaviruses including SARS-CoV"/>
  <result pre="including SARS-CoV [14], murine coronavirus [15], porcine deltacoronavirus [12], and" exact="infectious" post="bronchitis virus [16]. Thus, cholesterol present in the cell"/>
  <result pre="SARS-CoV [14], murine coronavirus [15], porcine deltacoronavirus [12], and infectious" exact="bronchitis" post="virus [16]. Thus, cholesterol present in the cell membrane"/>
  <result pre="virus [16]. Thus, cholesterol present in the cell membrane and" exact="viral" post="envelope has been found to contribute to coronavirus replication"/>
  <result pre="to coronavirus replication by acting as a key component in" exact="viral" post="entry [3,11]. Moreover, cholesterol was recently shown to be"/>
  <result pre="on SARS-CoV infection, which resulted in a significant reduction in" exact="viral" post="mRNA [14]. It was observed that cholesterol depletion impaired"/>
  <result pre="viral mRNA [14]. It was observed that cholesterol depletion impaired" exact="viral" post="entry and virus-induced fusion, suggesting that cholesterol is important"/>
  <result pre="suggest an essential role of lipid rafts and cholesterol in" exact="viral" post="entry, specific confirmation in vivo is needed. The seemingly"/>
  <result pre="may be directed against SARS-CoV-2. 3. Cholesterol-Lowering, Cardiovascular Complications of" exact="Acute" post="Respiratory Viruses In addition to the importance of cardiovascular"/>
  <result pre="be directed against SARS-CoV-2. 3. Cholesterol-Lowering, Cardiovascular Complications of Acute" exact="Respiratory" post="Viruses In addition to the importance of cardiovascular risk"/>
  <result pre="of Acute Respiratory Viruses In addition to the importance of" exact="cardiovascular" post="risk factors in exacerbating acute respiratory infections [3,10], there"/>
  <result pre="addition to the importance of cardiovascular risk factors in exacerbating" exact="acute" post="respiratory infections [3,10], there is also evidence showing that"/>
  <result pre="to the importance of cardiovascular risk factors in exacerbating acute" exact="respiratory" post="infections [3,10], there is also evidence showing that viral"/>
  <result pre="the importance of cardiovascular risk factors in exacerbating acute respiratory" exact="infections" post="[3,10], there is also evidence showing that viral infections"/>
  <result pre="acute respiratory infections [3,10], there is also evidence showing that" exact="viral" post="infections may cause cardiac complications [6]. Accordingly, previous studies"/>
  <result pre="respiratory infections [3,10], there is also evidence showing that viral" exact="infections" post="may cause cardiac complications [6]. Accordingly, previous studies have"/>
  <result pre="may cause cardiac complications [6]. Accordingly, previous studies have established" exact="acute" post="respiratory viral infections such as those caused by influenza"/>
  <result pre="cause cardiac complications [6]. Accordingly, previous studies have established acute" exact="respiratory" post="viral infections such as those caused by influenza virus"/>
  <result pre="cardiac complications [6]. Accordingly, previous studies have established acute respiratory" exact="viral" post="infections such as those caused by influenza virus and"/>
  <result pre="complications [6]. Accordingly, previous studies have established acute respiratory viral" exact="infections" post="such as those caused by influenza virus and coronaviruses"/>
  <result pre="as those caused by influenza virus and coronaviruses to trigger" exact="cardiovascular" post="(CV) complications such as acute coronary syndrome (ACS) [19],"/>
  <result pre="virus and coronaviruses to trigger cardiovascular (CV) complications such as" exact="acute" post="coronary syndrome (ACS) [19], myocarditis, arrhythmias [20], and heart"/>
  <result pre="coronaviruses to trigger cardiovascular (CV) complications such as acute coronary" exact="syndrome" post="(ACS) [19], myocarditis, arrhythmias [20], and heart failure (HF)"/>
  <result pre="such as acute coronary syndrome (ACS) [19], myocarditis, arrhythmias [20]," exact="and heart" post="failure (HF) acceleration. There have been several reports on"/>
  <result pre="as acute coronary syndrome (ACS) [19], myocarditis, arrhythmias [20], and" exact="heart" post="failure (HF) acceleration. There have been several reports on"/>
  <result pre="caused by COVID-19 may result in the development of fulminant" exact="myocarditis" post="[6,10,21]. Such mechanisms have also been reported in previous"/>
  <result pre="myocarditis [6,10,21]. Such mechanisms have also been reported in previous" exact="viral" post="epidemics such as SARS-CoV and Middle East respiratory syndrome"/>
  <result pre="in previous viral epidemics such as SARS-CoV and Middle East" exact="respiratory" post="syndrome (MERS), which have been characterised by cytokine storms"/>
  <result pre="previous viral epidemics such as SARS-CoV and Middle East respiratory" exact="syndrome" post="(MERS), which have been characterised by cytokine storms resulting"/>
  <result pre="other organs [26]. Shi et al. further proposed that the" exact="acute" post="inflammatory response that has been reported in COVID-19 might"/>
  <result pre="finally resulting in atherothrombotic complications. Thrombo-inflammation can further exacerbate cardiac" exact="ischemia" post="and injury [22]. An additional mechanism possibly explaining the"/>
  <result pre="for the ACE2 receptor, which is highly expressed in the" exact="heart" post="[3,6,22], suggesting the possibility of direct viral infection of"/>
  <result pre="expressed in the heart [3,6,22], suggesting the possibility of direct" exact="viral infection" post="of the heart. This hypothesis is further supported by"/>
  <result pre="in the heart [3,6,22], suggesting the possibility of direct viral" exact="infection" post="of the heart. This hypothesis is further supported by"/>
  <result pre="further supported by previous reports detecting the presence of the" exact="viral" post="genome in 35% of SARS-CoV infected autopsied hearts [6,27],"/>
  <result pre="with baseline CVD, being at very high or extremely high" exact="cardiovascular" post="risk, require optimal intensive statin therapy with maximally tolerated"/>
  <result pre="plaque-stabilisation effects, the pleiotropic effects of statins include attenuation of" exact="chronic" post="low-grade inflammation [35] and the immune response to infection."/>
  <result pre="of statins (Figure 1B). 4. Use of Statins in Human" exact="Viral" post="Infections Although there has been almost no evidence on"/>
  <result pre="statins (Figure 1B). 4. Use of Statins in Human Viral" exact="Infections" post="Although there has been almost no evidence on the"/>
  <result pre="drugs have previously been investigated in the treatment of other" exact="acute" post="respiratory viral infections such as influenza [37,38,39]. A study"/>
  <result pre="have previously been investigated in the treatment of other acute" exact="respiratory" post="viral infections such as influenza [37,38,39]. A study of"/>
  <result pre="previously been investigated in the treatment of other acute respiratory" exact="viral" post="infections such as influenza [37,38,39]. A study of 1055"/>
  <result pre="been investigated in the treatment of other acute respiratory viral" exact="infections" post="such as influenza [37,38,39]. A study of 1055 adult"/>
  <result pre="viral infections such as influenza [37,38,39]. A study of 1055" exact="adult" post="patients with viral pneumonia found lower rates of mortality"/>
  <result pre="as influenza [37,38,39]. A study of 1055 adult patients with" exact="viral pneumonia" post="found lower rates of mortality and intubation with continued"/>
  <result pre="influenza [37,38,39]. A study of 1055 adult patients with viral" exact="pneumonia" post="found lower rates of mortality and intubation with continued"/>
  <result pre="A study of 1055 adult patients with viral pneumonia found" exact="lower" post="rates of mortality and intubation with continued use of"/>
  <result pre="0.26; 95% confidence interval (CI): 0.08â€&quot;0.81) [37]. Similar to SARS-CoV," exact="hepatitis C" post="viral (HCV) replication is closely associated with lipid metabolism,"/>
  <result pre="confidence interval (CI): 0.08â€&quot;0.81) [37]. Similar to SARS-CoV, hepatitis C" exact="viral" post="(HCV) replication is closely associated with lipid metabolism, and"/>
  <result pre="are expected to disrupt this mechanism [40]. Statin treatment in" exact="chronic" post="HCV was shown to increase the clearance of the"/>
  <result pre="down-regulate HCV replication [41], and resulted in clinical reduction in" exact="hepatocellular carcinoma" post="[41,42]. Additionally, a meta-analysis by Chopra et al. showed"/>
  <result pre="HCV replication [41], and resulted in clinical reduction in hepatocellular" exact="carcinoma" post="[41,42]. Additionally, a meta-analysis by Chopra et al. showed"/>
  <result pre="Chopra et al. showed that statin use was associated with" exact="lower" post="mortality after pneumonia (OR 0.62, 95% CI: 0.54â€&quot;0.71) [43]."/>
  <result pre="showed that statin use was associated with lower mortality after" exact="pneumonia" post="(OR 0.62, 95% CI: 0.54â€&quot;0.71) [43]. A significant complication"/>
  <result pre="95% CI: 0.54â€&quot;0.71) [43]. A significant complication of the COVID-19" exact="infection" post="is the development of ARDS. Approximately 5% of COVID-19"/>
  <result pre="et al. [45] investigated the impact of pravastatin therapy on" exact="ventilator-associated pneumonia" post="(VAP) frequency and mortality. The authors showed that the"/>
  <result pre="al. [45] investigated the impact of pravastatin therapy on ventilator-associated" exact="pneumonia" post="(VAP) frequency and mortality. The authors showed that the"/>
  <result pre="mortality in patients with VAP [46]. However, this study was" exact="limited" post="by a short duration of simvastatin administration, which was"/>
  <result pre="with VAP [46]. However, this study was limited by a" exact="short" post="duration of simvastatin administration, which was probably administered too"/>
  <result pre="focused on statin therapy to prevent sepsis or against community-acquired" exact="infections" post="[37,38,47] supported a role for these drugs in severe"/>
  <result pre="supported a role for these drugs in severe infections. Nevertheless," exact="total" post="cholesterol levels in admitted COVID-19 patients can be extremely"/>
  <result pre="A recent study revealed that COVID-19 patients had sharply decreased" exact="total" post="cholesterol and low-density lipoprotein cholesterol (LDL-C) levels (3.70 Â±"/>
  <result pre="&amp;lt; 0.001 for both) [48]. Although several mechanisms for the" exact="acute" post="fall in cholesterol were suggested, it still remains unclear"/>
  <result pre="and these therapies might be better suited earlier in the" exact="disease" post="course prior to critical care admission. Lastly, a recent"/>
  <result pre="whether such host-response modulating drugs may promote a milder clinical" exact="infection" post="if initiated early in the disease process. We also"/>
  <result pre="promote a milder clinical infection if initiated early in the" exact="disease" post="process. We also should keep in mind the possible"/>
  <result pre="We also should keep in mind the possible occurrence of" exact="muscle" post="symptoms during the course of COVID-19. While myalgias are"/>
  <result pre="course of COVID-19. While myalgias are easily attributable to SARS-CoV-2" exact="infection" post="in statin untreated patients, their differential diagnosis may be"/>
  <result pre="severe manifestations of COVID-19 to prevent some of the life-threatening" exact="cardiovascular" post="complications. Author Contributions Conceptualization, M.B.; literature search, M.B., S.C.,"/>
  <result pre="of coronavirus pandemic: May it help to kill, if so-whom:" exact="Disease" post="or the person?J. Clin. Med.20209146410.3390/jcm905146432414182 3.KatsikiN.BanachM.MikhailidisD.Lipid-lowering therapy and renin-angiotensin-aldosterone"/>
  <result pre="al.Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-Infected" exact="pneumonia" post="in Wuhan, ChinaJAMA20203231061106910.1001/jama.2020.158532031570 5.WuZ.McGooganJ.M.Characteristics of and important lessons from"/>
  <result pre="Wuhan, ChinaJAMA20203231061106910.1001/jama.2020.158532031570 5.WuZ.McGooganJ.M.Characteristics of and important lessons from the coronavirus" exact="disease" post="2019 (COVID-19) outbreak in china: Summary of a report"/>
  <result pre="report of 72 314 cases from the Chinese center for" exact="disease" post="control and preventionJAMA20203231239124210.1001/jama.2020.264832091533 6.GuoT.FanY.ChenM.WuX.ZhangL.HeT.WangH.WanJ.WangX.LuZ.Cardiovascular implications of fatal outcomes of"/>
  <result pre="preventionJAMA20203231239124210.1001/jama.2020.264832091533 6.GuoT.FanY.ChenM.WuX.ZhangL.HeT.WangH.WanJ.WangX.LuZ.Cardiovascular implications of fatal outcomes of patients with coronavirus" exact="disease" post="2019 (COVID-19)JAMA Cardiol.202010.1001/jamacardio.2020.1017 7.SahebkarA.KotaniK.SerbanC.UrsoniuS.MikhailidisD.P.JonesS.R.RayK.K.BlahaM.J.RyszJ.TothP.P.et al.Statin therapy reduces plasma endothelin-1"/>
  <result pre="8.BianconiV.SahebkarA.BanachM.PirroM.Statins, haemostatic factors and thrombotic riskCurr. Opin. Cardiol.20173246046610.1097/HCO.000000000000039728266936 9.SahebkarA.SerbanC.UrsoniuS.Lipid and" exact="Blood" post="Pressure Meta-analysis Collaboration (LBPMC) Group. The impact of statin"/>
  <result pre="randomised placebo-controlled trialsThromb. Haemost.201611552053210.1160/th15-08-062026632869 10.MadjidM.Safavi-NaeiniP.SolomonS.D.VardenyO.Potential effects of coronaviruses on the" exact="cardiovascular" post="system: A reviewJAMA Cardiol.202010.1001/jamacardio.2020.1286 11.BaglivoM.BaronioM.NataliniG.BeccariT.ChiurazziP.FulcheriE.PetraliaP.P.MicheliniS.FiorentiniG.MiggianoG.A.et al.Natural small molecules as"/>
  <result pre="play an important role in the early stage of severe" exact="acute" post="respiratory syndrome-coronavirus life cycleMicrobes Infect.200799610210.1016/j.micinf.2006.10.01517194611 14.LuY.LiuD.X.TamJ.P.Lipid rafts are involved"/>
  <result pre="an important role in the early stage of severe acute" exact="respiratory" post="syndrome-coronavirus life cycleMicrobes Infect.200799610210.1016/j.micinf.2006.10.01517194611 14.LuY.LiuD.X.TamJ.P.Lipid rafts are involved in"/>
  <result pre="16.GuoH.HuangM.YuanQ.WeiY.GaoY.MaoL.GuL.TanY.W.ZhongY.LiuD.et al.The important role of lipid raft-mediated attachment in the" exact="infection" post="of cultured cells by coronavirus infectious bronchitis virus beaudette"/>
  <result pre="raft-mediated attachment in the infection of cultured cells by coronavirus" exact="infectious" post="bronchitis virus beaudette strainPLoS ONE201712e017012310.1371/journal.pone.017012328081264 17.WangH.YangP.LiuK.GuoF.ZhangY.ZhangG.JiangC.SARS coronavirus entry into"/>
  <result pre="attachment in the infection of cultured cells by coronavirus infectious" exact="bronchitis" post="virus beaudette strainPLoS ONE201712e017012310.1371/journal.pone.017012328081264 17.WangH.YangP.LiuK.GuoF.ZhangY.ZhangG.JiangC.SARS coronavirus entry into host"/>
  <result pre="18.MeherG.BhattacharjyaS.ChakrabortyH.Membrane cholesterol modulates oligomeric status and peptide-membrane interaction of severe" exact="acute" post="respiratory syndrome coronavirus fusion peptideJ. Phys. Chem. B2019123106541066210.1021/acs.jpcb.9b0845531743644 19.NguyenJ.L.YangW.ItoK.MatteT.D.ShamanJ.KinneyP.L.Seasonal"/>
  <result pre="cholesterol modulates oligomeric status and peptide-membrane interaction of severe acute" exact="respiratory" post="syndrome coronavirus fusion peptideJ. Phys. Chem. B2019123106541066210.1021/acs.jpcb.9b0845531743644 19.NguyenJ.L.YangW.ItoK.MatteT.D.ShamanJ.KinneyP.L.Seasonal influenza"/>
  <result pre="modulates oligomeric status and peptide-membrane interaction of severe acute respiratory" exact="syndrome" post="coronavirus fusion peptideJ. Phys. Chem. B2019123106541066210.1021/acs.jpcb.9b0845531743644 19.NguyenJ.L.YangW.ItoK.MatteT.D.ShamanJ.KinneyP.L.Seasonal influenza infections"/>
  <result pre="respiratory syndrome coronavirus fusion peptideJ. Phys. Chem. B2019123106541066210.1021/acs.jpcb.9b0845531743644 19.NguyenJ.L.YangW.ItoK.MatteT.D.ShamanJ.KinneyP.L.Seasonal influenza" exact="infections" post="and cardiovascular disease mortalityJAMA Cardiol.2016127428110.1001/jamacardio.2016.043327438105 20.WuC.PostemaP.G.ArbeloE.BehrE.R.BezzinaC.R.NapolitanoC.RobynsT.ProbstV.Schulze-BahrE.RemmeC.A.et al.SARS-CoV-2, COVID-19 and"/>
  <result pre="coronavirus fusion peptideJ. Phys. Chem. B2019123106541066210.1021/acs.jpcb.9b0845531743644 19.NguyenJ.L.YangW.ItoK.MatteT.D.ShamanJ.KinneyP.L.Seasonal influenza infections and" exact="cardiovascular disease" post="mortalityJAMA Cardiol.2016127428110.1001/jamacardio.2016.043327438105 20.WuC.PostemaP.G.ArbeloE.BehrE.R.BezzinaC.R.NapolitanoC.RobynsT.ProbstV.Schulze-BahrE.RemmeC.A.et al.SARS-CoV-2, COVID-19 and inherited arrhythmia syndromesHeart"/>
  <result pre="fusion peptideJ. Phys. Chem. B2019123106541066210.1021/acs.jpcb.9b0845531743644 19.NguyenJ.L.YangW.ItoK.MatteT.D.ShamanJ.KinneyP.L.Seasonal influenza infections and cardiovascular" exact="disease" post="mortalityJAMA Cardiol.2016127428110.1001/jamacardio.2016.043327438105 20.WuC.PostemaP.G.ArbeloE.BehrE.R.BezzinaC.R.NapolitanoC.RobynsT.ProbstV.Schulze-BahrE.RemmeC.A.et al.SARS-CoV-2, COVID-19 and inherited arrhythmia syndromesHeart"/>
  <result pre="and cardiovascular disease mortalityJAMA Cardiol.2016127428110.1001/jamacardio.2016.043327438105 20.WuC.PostemaP.G.ArbeloE.BehrE.R.BezzinaC.R.NapolitanoC.RobynsT.ProbstV.Schulze-BahrE.RemmeC.A.et al.SARS-CoV-2, COVID-19 and inherited" exact="arrhythmia" post="syndromesHeart Rhythm.202010.1016/j.hrthm.2020.03.024 21.HuangC.WangY.LiX.RenL.ZhaoJ.HuY.ZhangL.FanG.XuJ.GuX.et al.Clinical features of patients infected with"/>
  <result pre="al.Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: A single-centered, retrospective, observational studyLancet Respir."/>
  <result pre="8: RAS and reproductive hormones in COVID-19â€&quot;Can we end this" exact="viral" post="series?Arch. Med. Sci.202010.5114/aoms.2020.96497 25.BonowR.O.FonarowG.C.Oâ€™GaraP.T.YancyC.W.Association of coronavirus disease 2019 (COVID-19)"/>
  <result pre="we end this viral series?Arch. Med. Sci.202010.5114/aoms.2020.96497 25.BonowR.O.FonarowG.C.Oâ€™GaraP.T.YancyC.W.Association of coronavirus" exact="disease" post="2019 (COVID-19) with myocardial injury and mortalityJAMA Cardiol.202010.1001/jamacardio.2020.1105 26.ChannappanavarR.PerlmanS.Pathogenic"/>
  <result pre="inflammation left ventricular function, hospitalizations and mortality in patients with" exact="dilated" post="cardiomyopathyâ€&quot;5-year follow-upLipids Health Dis.2013124710.1186/1476-511X-12-4723566246 30.HanssonG.K.LibbyP.TabasI.Inflammation and plaque vulnerabilityJ. Intern."/>
  <result pre="insight to pleiotropic effectsPharmacol. Res.201813523023810.1016/j.phrs.2018.08.01430120976 36.KoushkiK.ShahbazS.K.MashayekhiK.SadeghiM.ZayeriZ.D.TabaM.Y.BanachM.Al-RasadiK.JohnstonT.P.SahebkarA.Anti-inflammatory action of statins in" exact="cardiovascular" post="disease: The role of inflammasome and toll-like receptor pathwaysClin."/>
  <result pre="Allergy Immunol.202010.1007/s12016-020-08791-9 37.HenryC.ZaizafounM.StockE.GhamandeS.ArroligaA.C.WhiteH.D.Impact of angiotensin-converting enzyme inhibitors and statins on" exact="viral" post="pneumoniaProc (Bayl. Univ. Med. Cent.)20183141942310.1080/08998280.2018.149929330948970 38.MehrbodP.OmarA.R.Hair-BejoM.HaghaniA.IderisA.Mechanisms of action and"/>
  <result pre="40.WangC.GaleM.KellerB.C.HuangH.BrownM.S.GoldsteinJ.L.YeJ.Identification of FBL2 as a geranylgeranylated cellular protein required for" exact="hepatitis C" post="virus RNA replicationMol. Cell.20051842543410.1016/j.molcel.2005.04.00415893726 41.AliN.AllamH.BaderT.MayR.BasalingappaK.M.BerryW.L.ChandrakesanP.QuD.WeygantN.BronzeM.S.et al.Fluvastatin interferes with hepatitis"/>
  <result pre="hepatitis C virus RNA replicationMol. Cell.20051842543410.1016/j.molcel.2005.04.00415893726 41.AliN.AllamH.BaderT.MayR.BasalingappaK.M.BerryW.L.ChandrakesanP.QuD.WeygantN.BronzeM.S.et al.Fluvastatin interferes with" exact="hepatitis C" post="virus replication via microtubule bundling and a doublecortin-like kinase-mediated"/>
  <result pre="systematic review and meta-analysisAm. J. Med.20121251111112310.1016/j.amjmed.2012.04.01122835463 44.collab: WHOClinical Management of" exact="Severe" post="Acute Respiratory Infection When COVID-19 Is Suspected2020Available online: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected(accessed"/>
  <result pre="review and meta-analysisAm. J. Med.20121251111112310.1016/j.amjmed.2012.04.01122835463 44.collab: WHOClinical Management of Severe" exact="Acute" post="Respiratory Infection When COVID-19 Is Suspected2020Available online: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected(accessed on"/>
  <result pre="and meta-analysisAm. J. Med.20121251111112310.1016/j.amjmed.2012.04.01122835463 44.collab: WHOClinical Management of Severe Acute" exact="Respiratory" post="Infection When COVID-19 Is Suspected2020Available online: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected(accessed on 11"/>
  <result pre="meta-analysisAm. J. Med.20121251111112310.1016/j.amjmed.2012.04.01122835463 44.collab: WHOClinical Management of Severe Acute Respiratory" exact="Infection" post="When COVID-19 Is Suspected2020Available online: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected(accessed on 11 April"/>
  <result pre="11 April 2020) 45.MakrisD.ManoulakasE.KomnosA.PapakrivouE.TzovarasN.HovasA.ZintzarasE.ZakynthinosE.Effect of pravastatin on the frequency of" exact="ventilator-associated pneumonia" post="and on intensive care unit mortality: Open-label, randomized studyCrit."/>
  <result pre="April 2020) 45.MakrisD.ManoulakasE.KomnosA.PapakrivouE.TzovarasN.HovasA.ZintzarasE.ZakynthinosE.Effect of pravastatin on the frequency of ventilator-associated" exact="pneumonia" post="and on intensive care unit mortality: Open-label, randomized studyCrit."/>
  <result pre="Vasc. Pharmacol.20131179580010.2174/157016111131105001822272901 48.HuX.ChenD.WuL.HeG.YeW.Low serum cholesterol level among patients with COVID-19" exact="infection" post="in Wenzhou, ChinaAvailable online: 10.2139/ssrn.3544826(accessed on 21 February 2020)"/>
  <result pre="evidence on direct interactionArch. Med. Sci.20201649049610.5114/aoms.2020.9465532399094 50.SouthA.M.DizD.I.ChappellM.C.COVID-19, ACE2, and the" exact="cardiovascular" post="consequencesAm. J. Physiol. Heart Circ. Physiol.2020318H1084H109010.1152/ajpheart.00217.202032228252 51.NikolicD.BanachM.ChianettaR.LuzzuL.M.Pantea StoianA.DiaconuC.C.CitarrellaR.MontaltoG.RizzoM.An overview"/>
  <result pre="Med. Sci.20201649049610.5114/aoms.2020.9465532399094 50.SouthA.M.DizD.I.ChappellM.C.COVID-19, ACE2, and the cardiovascular consequencesAm. J. Physiol." exact="Heart" post="Circ. Physiol.2020318H1084H109010.1152/ajpheart.00217.202032228252 51.NikolicD.BanachM.ChianettaR.LuzzuL.M.Pantea StoianA.DiaconuC.C.CitarrellaR.MontaltoG.RizzoM.An overview of statin-induced myopathy and"/>
  <result pre="J. Physiol. Heart Circ. Physiol.2020318H1084H109010.1152/ajpheart.00217.202032228252 51.NikolicD.BanachM.ChianettaR.LuzzuL.M.Pantea StoianA.DiaconuC.C.CitarrellaR.MontaltoG.RizzoM.An overview of statin-induced" exact="myopathy" post="and perspectives for the futureExpert Opin. Drug Saf.202010.1080/14740338.2020.174743132233708 52.BanachM.PensonP.E.FrasZ.VrablikM.PellaD.ReinerÅ½.NabaviS.M.SahebkarA.KayikciogluM.DaccordM.Brief"/>
  <result pre="futureExpert Opin. Drug Saf.202010.1080/14740338.2020.174743132233708 52.BanachM.PensonP.E.FrasZ.VrablikM.PellaD.ReinerÅ½.NabaviS.M.SahebkarA.KayikciogluM.DaccordM.Brief recommendations on the management of" exact="adult" post="patients with familial hypercholesterolemia during the COVID-19 pandemicPharmacol. Res.202015810489110.1016/j.phrs.2020.10489132389859"/>
  <result pre="Saf.202010.1080/14740338.2020.174743132233708 52.BanachM.PensonP.E.FrasZ.VrablikM.PellaD.ReinerÅ½.NabaviS.M.SahebkarA.KayikciogluM.DaccordM.Brief recommendations on the management of adult patients with" exact="familial" post="hypercholesterolemia during the COVID-19 pandemicPharmacol. Res.202015810489110.1016/j.phrs.2020.10489132389859 Figure 1 Proposed"/>
  <result pre="mechanism of the role of cholesterol and statins in severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. (A) Lipid rafts"/>
  <result pre="of the role of cholesterol and statins in severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) infection. (A) Lipid rafts rich"/>
  <result pre="the role of cholesterol and statins in severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) infection. (A) Lipid rafts rich in"/>
  <result pre="as docking sites for angiotensin-converting enzyme 2 (ACE2) receptors and" exact="viral" post="attachment via the S protein of SARS-CoV-2, which is"/>
  <result pre="is then taken into the cells by clathrin. In addition," exact="acute" post="infection with SARS-COV-2 and macrophages via paracrine factors can"/>
  <result pre="then taken into the cells by clathrin. In addition, acute" exact="infection" post="with SARS-COV-2 and macrophages via paracrine factors can lead"/>
  <result pre="occlusion of distal microvasculature. (B) Statins disrupt lipid rafts and" exact="viral" post="binding; reduce cholesterol; and have plaque stabilising, antithrombotic, and"/>
 </snippets>
</snippetsTree>
